Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study. Issue 166 (June 2018)

• Record Type: Journal Article
• Authors: Favaloro, Emmanuel J.; Bonar, Roslyn; Hollestelle, Martine J.; Jennings, Ian; Mohammed, Soma; Meijer, Piet; Woods, Timothy; Meiring, Muriel
• Is Part Of: Thrombosis research. Issue 166(2018)
• Page Start: 96
• Page End: 105
• Publication Date: 2018-06
• Subjects: ELISA enzyme linked immunosorbent assay -- GPIb glycoprotein Ib -- HMW high molecular weight (VWF) -- NAC N‑acetycysteine -- TTP thrombotic thrombocytopenic purpura -- VWF von Willebrand factor -- VWF:Ab VWF activity assays based on the binding of a monoclonal antibody (MAB) to a VWF A1 domain epitope -- VWF:Ag VWF antigen (protein level) -- VWF:CB VWF collagen binding -- VWF:GPIbM VWF activity assays based on spontaneous binding of VWF to a gain-of-function mutant GPIb fragment -- VWF:GPIbR VWF activity assays based on ristocetin-induced binding of VWF to a recombinant wild type GPIb fragment -- VWF:RCo VWF ristocetin cofactor -- VWD von Willebrand disease; von Willebrand disease, VWD -- von Willebrand factor, VWF -- High molecular weight sensitivity -- Laboratory testing -- VWD diagnosis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2018.04.015
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: von Willebrand disease (VWD), the most common inherited bleeding disorder, is due to deficiencies/defects in von Willebrand factor (VWF). Effective diagnosis requires testing for FVIII, VWF antigen and one or more VWF 'activity' assays. Classically, 'activity' is assessed using ristocetin cofactor (VWF:RCo), but collagen binding (VWF:CB) and/or other assays are used by many laboratories. This extensive international cross-laboratory study has specifically evaluated contemporary VWF activity assays for comparative sensitivity to reduction in high molecular weight (HMW) VWF, and their ability to differentiate type 1 vs 2A VWD-like samples. Materials and methods: A set of four samples representing step wise reduction in HMW VWF were tested by over 400 laboratories worldwide using various assays. A second set of two samples representing type 1 or type 2A VWD-like plasma was tested by a subset of 251 laboratories. Results: Combined data identified some differences between VWF activity assays, with sensitivity for reduction of HMW being highest for VWF:CB and VWF:GPIbM, intermediate for VWF:RCo and VWF:GPIbR, and lowest for VWF:Ab. 'Within' method analysis identified the Stago method as the most sensitive VWF:CB assay. A large variation in inter-laboratory CV (e.g., 7–24% for the normal sample) was also demonstrated for various methods. Although performance of various methods differed significantly, most laboratories correctly differentiated between type 1 and 2 samples, irrespective of VWF activity assay employed. Conclusions: These results hold significant clinical implications for diagnosis and therapy monitoring of VWD, as well as potential future diagnosis and therapy monitoring of thrombotic thrombocytopenic purpura (TTP). Highlights: von Willebrand disorders (VWD) are common and due to deficiencies/defects in von Willebrand factor (VWF). Activity assays have variable utility, in part due to differential sensitivity to high molecular weight (HMW) VWF. This study identifies HMW sensitivity in the order VWF:CB, VWF:GPIbM, VWF:RCo, VWF:GPIbR, VWF:Ab.This study identifies HMW sensitivity in the order VWF:CB, VWF:GPIbM, VWF:RCo, VWF:GPIbR, VWF:Ab. Other method differences are also highlighted, including utility in differentiating type 1 vs 2A VWD-like samples.